To determine the spectrum and impact of mycelial fungal infections, particularly those due to non-Aspergillus molds, 53 liver and heart transplant recipients with invasive mycelial infections were prospectively identified in a multicenter study. Invasive mycelial infections were due to Aspergillus species in 69.8% of patients, to non-Aspergillus hyalohyphomycetes in 9.4%, to phaeohyphomycetes in 9.4%, to zygomycetes in 5.7%, and to other causes in 5.7%. Infections due to mycelial fungi other than Aspergillus species were significantly more likely to be associated with disseminated ( ) and central nervous system ( ) infection than were P p .005 P p .07 those due to Aspergillus species. Overall mortality at 90 days was 54.7%. The associated mortality rate was 100% for zygomycosis, 80% for non-Aspergillus hyalohyphomycosis, 54% for aspergillosis, and 20% for phaeohyphomycosis. Thus, non-Aspergillus molds have emerged as significant pathogens in organ transplant recipients. These molds are more likely to be associated with disseminated infections and to be associated with poorer outcomes than is aspergillosis.
To determine the spectrum and impact of mycelial fungal infections, particularly those due to non-Aspergillus molds, 53 liver and heart transplant recipients with invasive mycelial infections were prospectively identified in a multicenter study. Invasive mycelial infections were due to Aspergillus species in 69.8% of patients, to non-Aspergillus hyalohyphomycetes in 9.4%, to phaeohyphomycetes in 9.4%, to zygomycetes in 5.7%, and to other causes in 5.7%. Infections due to mycelial fungi other than Aspergillus species were significantly more likely to be associated with disseminated ( ) and central nervous system ( ) infection than were P p .005 P p .07 those due to Aspergillus species. Overall mortality at 90 days was 54.7%. The associated mortality rate was 100% for zygomycosis, 80% for non-Aspergillus hyalohyphomycosis, 54% for aspergillosis, and 20% for phaeohyphomycosis. Thus, non-Aspergillus molds have emerged as significant pathogens in organ transplant recipients. These molds are more likely to be associated with disseminated infections and to be associated with poorer outcomes than is aspergillosis.
Invasive fungal infections have long been recognized as a significant complication in organ transplant recipients. A vast majority of infections in these patients are due to either Candida (35%-91%) or Aspergillus species (9%-52%), with other opportunistic fungi accounting for 1%-2% of the fungal infections [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . Within the past decade, however, infections due to infrequently encountered fungi (e.g., hyaline molds, dematiaceous filamentous fungi, and zygomycetes) have become in-creasingly common in immunocompromised hosts, most notably, hematopoeitic stem cell transplant recipients [11, 12] . These trends are worrisome, given that the opportunistic molds are often refractory to conventional antifungal agents. Innate resistance or erratic susceptibility to amphotericin B is characteristic of certain fungi (e.g., Aspergillus terreus, Scedosporium apiospermum, and Scedosporium prolificans) [13] [14] [15] [16] . The advent of novel antifungal agents represents an advance in the management of invasive mycoses. However, fungi such as S. prolificans and the zygomycetes are also resistant to the currently available triazoles and the echinocandins [13] [14] [15] [16] .
The spectrum and overall impact of these emerging fungal pathogens has not been fully defined in solidorgan transplant recipients. In a prospective, multicenter study, we sought to determine the types of mycelial fungi associated with infections in liver and heart trans- 
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plant recipients, to define the characteristics of patients developing these infections, and to discern the outcome of the infections.
METHODS
The study population comprised 53 consecutive, prospectively identified liver and heart transplant recipients with invasive mold infections who were admitted to the participating sites from December 1998 through [18] . Proven mold infection was defined as a histopathologic examination that revealed tissue invasion and a culture result positive for the mold, or as a positive culture result for a sample obtained by sterile procedure from normally sterile and clinically or radiologically abnormal site consistent with infection [18] . The criteria for probable invasive fungal infection [18] were used for the diagnosis of pulmonary infections only. Involvement of у2 noncontiguous organ sites or the CNS was considered to indicate disseminated infection. The antifungal regimen used and the duration of therapy were at the discretion of health care providers at individual institutions. Infection was considered early if it occurred !90 days and late if it occurred у90 days after transplantation.
Detection of Aspergillus species in cultures of respiratory tract specimens is common, and differentiation of colonization from invasive infection is difficult in lung transplant recipients. Therefore, given that the diagnosis of probable invasive aspergillosis can be unreliable in lung transplant recipients, and given the overall lower prevalence of invasive mycelial infections in renal transplant recipients, the study was limited to liver and heart transplant recipients. Institutional review board approval was obtained in accordance with local requirements.
Statistical analysis was performed using Prophet statistical software, version 6.0 (AbTech). Categorical variables were compared using the x 2 test or Fisher's exact test, and continuous variables were compared using Student's t test or the MannWhitney U test. A logistic model was used to evaluate the effects of multiple risk factors on outcome. A x 2 analysis for trend was used to estimate a dose response for the risk for mortality in an individual patient.
RESULTS
Patient characteristics.
Of 53 patients with invasive mold infections, 36 were liver transplant recipients (including 2 recipients of liver/kidney transplants and 1 recipient of a liver/ small-bowel transplant), and 17 were heart transplant recipients (including 1 heart/lung transplant recipient). The median age Spectrum and characteristics of fungal infections. Etiologic pathogens were as follows: Aspergillus species, in 37 (69.8%) of the 53 patients; non-Aspergillus hyalohyphomycetes (S. apiospermum and Fusarium species), in 5 (9.4%); phaeohyphomycetes (dematiaceous fungi), in 5 (9.4%); zygomycetes (Rhizopus and Mucor species), in 3 (5.7%); and Trichophyton rubrum, in 1 (1.8%). The types of specific pathogens recovered from the patients are outlined in table 1. In 2 patients, mycelial fungal hyphae were documented histopathologically (by lung nodule biopsy in one patient and in CNS blood vessels on autopsy in another). However, cultures were not performed for these patients; they were considered to have had an unidentified mycelial fungal infection.
A total of 30 (56.6%) of the 53 patients had pulmonary infections only, and 12 (22.6%) had disseminated infection. Any pulmonary, CNS, or cutaneous site involvement was documented in 37 (69.8%), 5 (9.4%), and 5 (9.4%) of the 53 patients, respectively (the 2 unidentified mold infections were excluded here). Of the 34 patients with lung involvement in whom the diagnosis was established antemortem, the type of the infiltrate was nodular in 32%, focal consolidation in 32%, diffuse or bilateral alveolar in 18%, cavitary in 6%, and unspecified in 12%.
The risk of disseminated infection differed significantly between specific types of mycelial fungal infections. Infections due to mycelial fungi other than Aspergillus species were more likely to be disseminated than were infections due to Aspergillus species (7 [50%] of 14 infections vs. 4 
[10.8%] of 37 infections;
). Disseminated infection was present in 3 (100%) of P p .005 the 3 patients infected with zygomycetes, 3 (60%) of the 5 patients infected with non-Aspergillus hyalohyphomycetes, 1 (20%) of the 5 patients infected with phaeohyphomycetes, and ). The rate of retransplan-P p .051 tation (14.8% vs. 30.8%) tended to be higher, and the rate of transplant rejection preceding infection tended to be lower (34.6% vs. 51.9%) in the patients with early-onset infection, compared with those who had late-onset infection (table 4) . The risk of dissemination, CNS infection, and risk factors (e.g., the incidence of dialysis preceding infection) did not differ significantly between patients with infections that occurred in the early as opposed to the late posttransplantation period (table 4).
Antifungal prophylaxis had been administered to 8% of the patients with aspergillosis and to 21.4% of those with other mold infections ( ). Antifungal agents for prophylaxis P p NS consisted of fluconazole (in 1 patient) and low-dose amphotericin B (in 2 patients) with aspergillosis, low-dose amphotericin B (in 1 patient) with the non-Aspergillus hyalohyphomycoses, fluconazole (in 1 patient) with zygomycoses, and itraconazole (in 1 patient) with phaeohyphomycoses.
Patients with Aspergillus infection tended to have a lower rate of preceding CMV infection than did patients with other mycelial fungal infections (27% vs. 57.1%;
; (table 6 ). The mortality rate was higher among liver transplant recipients than among heart transplant recipients with invasive mycelial fungal infections, with the difference approaching statistical significance (  ; table 6 ). Trend analysis for the P p .051 risk of mortality (with retransplantation, dialysis, CMV infection, and disseminated fungal infection as the factors) showed that the mortality rate was 11.8% when none of the above factors were present (OR, 1.0); 58.8%, when 1 factor was present (OR, 10.71; 95% CI, 1.4-83.8); 81.8%, when 2 factors were present (OR, 33.75; 95% CI, 1.6-702); and 100%, when у3 factors were present (OR, undefined;
, by x 2 test for P p .0004 trend). Because 80% of the intubated patients also had undergone retransplantation, required dialysis, and had CMV infection, intubation was excluded from this analysis.
In 
DISCUSSION
The opportunistic molds include a diverse group of fungi that are classified as having either nonseptate (e.g., zygomycetes) or septate hyphae. Although this classification may be considered mycologically oversimplistic, the septate molds further include fungi that have either hyaline hyphae (i.e., without pigment in the cell wall; e.g., hyalohyphomycoses) or phaeohyphomycoses that have dematiaceous or pigmented cell walls containing melanin. For the purpose of this report, Aspergillus species (hyaline mold) are discussed separately from the non-Aspergillus hyalohyphomycoses. Our study documents the growing importance of these mycelial fungi in organ transplant recipients. A body of work involving organ transplant recipients through the early 1990s has documented that only 2% of all mycelial infections in these patients were due to fungi other than Aspergillus species [1] [2] [3] [4] [5] [6] [7] [8] [9] 20] . We show that non-Aspergillus mycelial fungi now account for 27% of mold infections. Our data also document important differences in the characteristics and outcome of specific types of mycelial fungal infections.
A total of 50%-60% of liver and 20%-35% of heart transplant recipients with invasive aspergillosis have been shown to have disseminated infection [21] [22] [23] . Disseminated infection has been documented in 13% of organ transplant recipients with zygomycosis [24] . In addition, 39% of zygomycotic infections that occur after transplantation have been of the rhinoorbitocerebral form [24] . Thus, disseminated or CNS involvement may occur in up to 52% of transplant recipients with zygomycosis. Disseminated infections have been reported in 30%-35% of patients with Scedosporium infections [25] [26] [27] . A vast majority of the phaeohyphomycotic infections in transplant recipients comprise skin and soft-tissue infections (79%), with systemic invasive infections occurring in 21% [28, 29] . Most Fusarium infections in organ transplant recipients are localized, which is not the case in bone marrow transplant recipients [30] . To our knowledge, a total of 6 cases of fusariosis have been reported in organ transplant recipients, of which only 1 (16.6%) was a disseminated infection [30] .
Our data show that mold infections other than aspergillosis were significantly more likely to be associated with disseminated infections: 4 (10.8%) of the 37 Aspergillus infections were disseminated, compared with 7 (50%) of the 14 other mold infections ( ). CNS involvement was present in 5% of P p .005 the patients with Aspergillus infection, compared with 14.3% of those with other mold infections ( ). Patients with P p .07 aspergillosis, on the other hand, were more likely to have infection that was limited to the lungs. Therefore, it appears that, although the risk of dissemination of Aspergillus infection in our cohort of patients is lower [17] , the risk of dissemination of infections due to the other molds has remained unchanged (or is higher) than has traditionally been documented in transplant recipients.
Precise reasons for a lower risk of disseminated infection with Aspergillus species than for other mold infections are not clear. It is unlikely that aspergillosis as opposed to the other mold infections was diagnosed earlier during the course of illness and that delayed diagnosis occurred selectively for the non-Aspergillus molds and accounted for a higher frequency of disseminated infection due to these molds. Although surveillance tests using the Platelia galactomannan antigen can lead to an earlier diagnosis of invasive aspergillosis, our patients were not monitored in this manner. Antifungal prophylaxis with the azoles (fluconazole) for candidiasis was shown to cor- relate with a higher risk of developing invasive mycelial infections that were innately resistant to this agent [31] . However, in our study, patients with Aspergillus infection did not differ from those with other mold infections with regard to the proportion who received prophylaxis and the type of antifungal agents used. Patients infected with non-Aspergillus molds, however, were more likely to have prior CMV infection, indicating moreprofound immunosuppression, which may explain the higher rate of dissemination. In addition, calcineurin and target of rapamycin (TOR) pathways have been shown to affect a variety of cellular physiological processes, including cell cycle progression, morphogenesis, cation homeostasis, and virulence, in a number of pathogenic yeasts and molds, including Aspergillus species [32] [33] [34] . Calcineurin regulates hyphal growth and has been shown to be essential for cell cycle progression in Aspergillus nidulans [35, 36] . Inhibitors of calcineurin/TOR pathway are toxic in vitro against Aspergillus species [32] . Furthermore, calcineurin/TOR inhibitors-in particular, tacrolimus and sirolimus-were found to enhance the activity of antifungal agents in vitro and attenuate the growth of all Aspergillus species tested [37] . Although invasive aspergillosis continues to be observed in organ transplant recipients, currently used calcineurin/TOR inhibitors may have specific effects on clinical manifestations, tissue tropism or the risk of dissemination associated with this fungus as has been shown for Cryptococcus neoformans [38] .
Data from animal studies corroborate this clinical observation. In a mouse model of invasive aspergillosis, the immunosuppressive agents had no impact on survival [39] . However, histopathologic examination documented widely disseminated hy-phae in the brains of cyclosporine A-treated mice, whereas the brains of tacrolimus-and sirolimus-treated mice showed a nearly complete absence of Aspergillus hyphae [39] .
The outcome for patients with disseminated mycelial fungal infection has been poor. Disseminated infections due to zygomycetes in organ transplant recipients have been uniformly fatal [24] . The mortality rate for the rhinocerebral form of zyomycosis in transplant recipients whose cases were diagnosed antemortem was found to be 50% [24] . Of organ transplant recipients with S. apiospermum infection, 73% died; all patients with disseminated infection and 91% of those with CNS infection died [25] . Phaeohyphomycotic fungi belonging to the genera Dactylaria, Ochroconis, and Scolecobasidium are noteworthy for their neurotropic potential and predilection to cause brain abscesses. The reported mortality rate for patients with systemic invasive phaeohyphomycosis is 57% [29] . The mortality rate for our patients with invasive mycelial infection, particularly infection due to zygomycetes and the non-Aspergillus hyalohyphomycetes, exceeded the mortality rate for Aspergillus infection; all patients infected with zygomycetes and 80% of those infected with non-Aspergillus hyalohyphomycetes died. A higher rate of disseminated infection and currently available antifungal therapy that is largely ineffective against these fungi likely accounted for the dismal outcome for these patients.
The recent development of the echinocandins and the thirdgeneration triazoles has contributed towards an expanded armamentarium of antifungal drugs, particularly for treatment of Aspergillus infection. However, the echinocandins have limited in vitro activity against phaeohyphomycoses, Fusarium species, and the zygomycetes [14] . However, the new triazole agent voriconazole is a potentially promising drug for the treatment of S. apiospermum and phaeophyhomycotic fungal infections. Reports documenting the efficacy of voriconazole for S. apiospermum infections, including CNS infection, have been reported [25, [40] [41] [42] [43] . In pediatric patients with S. apiospermum infection who were treated with voriconazole, 83% had a successful outcome [44] . The triazoles, including voriconazole, are now regarded as the drugs of choice for treatment of dematiaceous fungal infection [45] . For infections due to other opportunistic molds (most notably, S. prolificans and the zygomycetes), the existing therapies remain suboptimal. Two investigational triazole compounds, posaconazole and ravuconazole, appear to be more active against Rhizopus species with a MIC 50 of 1-2 mg/mL, compared with 18 mg/mL for voriconazole [46] . A study involving an animal model has also suggested a potential role of posaconazole for this infection [47] . The efficacy of these novel antifungal agents or that of combination therapies for these molds, however, remains to be determined.
In summary, our study documents that non-Aspergillus mycelial fungi have emerged as significant and increasingly commonly occurring pathogens in transplant recipients. The nonAspergillus mycelial fungal infections were more likely to be disseminated and tended to be associated with poorer outcome, compared with aspergillosis. In this context, devising novel therapeutic approaches (e.g., combination antifungal or immunomodulatory therapies) and discerning the role of diagnostic strategies (including non-culture based assays) that may facilitate early diagnosis of these infections have now become an important consideration and a challenge.
